Toll-like receptor agonists and MALP-2S for cancer treatment
Toll-like receptor (TLR) agonists are a very promising new target for cancer treatment. Our proprietary drug candidate, the synthetically manufactured Macrophage Activating LipoPeptide-2, MALP-2S, is designed to specifically stimulate the TLR 2/6 dimer, which belongs to a family of receptors activating the innate immune system.
Aiming to stay focused in initial operations, MBiotec will primarily develop MALP-2S for pancreatic cancer. The COMP adopted a positive opinion recommending MALP-2S for designation as orphan medicinal product to the European Commission.
Business strategy: To maximize the potential of MALP-2S for cancer treatment by focusing on development strategy for pancreatic cancer. To gain fast market access and to develop other cancer indications subsequently.
To date, MBiotec has entered negotiations with several potential inventors/ partners to secure financing of the clinical development program for MALP-2S. Negotiations are expected to be finalized by mid 2009.